Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22565679 | 0.73 | CA9 (0.40) | CA9CA12CA2ELANEGPR3 | |
| SCHEMBL7347447 | 0.70 | CA12 (0.36) | CA9CA12CA2ATMELANE | |
| SCHEMBL1840637 | 0.68 | LMNA (0.41) | CA9CA12CA2ELANE | |
| SCHEMBL6992121 | 0.65 | ELANE (0.34) | CA9CA12CA2ELANE | |
| SCHEMBL11036902 | 0.64 | GPR3 (0.55) | CA9CA12CA2ELANEGPR3 | |
| Water SCHEMBL27659746 | 0.63 | CA9 (0.44) | CA9CA12CA2ELANEGPR3 | |
| SCHEMBL11748728 | 0.60 | GPR3 (0.39) | CA9CA12CA2ELANEGPR3 | |
| SCHEMBL31003510 | 0.60 | CA9 (0.46) | CA9CA12CA2ELANEGPR3 | |
| SCHEMBL62430 | 0.60 | CA9 (0.46) | CA9CA12CA2ELANEGPR3 | |
| SCHEMBL11005895 | 0.60 | CA12 (0.40) | CA9CA12CA2GPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274042-A1 | TREATMENT AND/OR PREVENTION OF MULTIPLE SCLEROSIS | Epiphany Biosciences, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009126327-A1 | TREATMENT AND/OR PREVENTION OF MULTIPLE SCLEROSIS | EPIPHANY BIOSCIENCES, INC. (US) | 2009-10-15 | — | — | WO | disclosed |